Are we under-monitoring in scleroderma ILD? Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or RA Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of Systemic Sclerosis… https://t.co/GJRWGxUnh3 https://t.co/vtCOXGe4H8

Dengue fever, a mosquitoborne viral illness, is increasing worldwide; during 2024, approximately 13 million cases have been reported in the Americas. 2010–2024, a total of 15,077 (38.6%) patients were hospitalized But the fatality rate is unchanged. 2023 DENV-3 recent outbreak in… https://t.co/BKrEmN4F6G https://t.co/WIXaPeex8Z

Sex Differences in Psoriatic Arthritis Dr. Catherine Bakewell shared key takeaways from a session presented Sunday morning by Dr. Laura Coates and Dr. Lihi Eder, as well as abstract 1709. https://t.co/eKAzPSDQLH https://t.co/ACYMgVSW89

Way Behind in Pediatric Rheumatology While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP).… https://t.co/O03bA0xWL8 https://t.co/vJYKgyYNwI

Chikungunya marches on, at a cost A recent article from BMC Global Health suggests that between 2011 and 2020, the mosquito-borne disease chikungunya, has disabled millions and likely amassed close to $50 billion in healthcare and disability-related costs in 110 countries.… https://t.co/TnDObv1obT https://t.co/yjMeBODuFv

Comparison of 139 incident RA-ILD pts vs 686 controls followed for >12 mos showed Higher inflammation (ESR OR 1.86, CRP OR 1.55) [not DAS, TJC, SJC] were signif assoc w/ ILD risk. Data from RABBIT - German Biologics register https://t.co/MMvfgVQfaL https://t.co/KKZEPmsLfk

Bimekizumab in PsA Showed Sustained Reductions in Disease Impact Dr. Eric Dein talks with Dr. Ana-Marie Orbai about abstract 0600, Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis… https://t.co/HiqIly6Kii https://t.co/sFyqHE6ug1

Small, suspended, post COVID randomized trial, guselkumab failed to show efficacy at reducing proteinuria in 33 SLE pts. Wk24 results, 56% placebo vs. 35% GUS for primary end point., No differences in secondary outcomes or adverse events https://t.co/27imkXkbUn https://t.co/yGdDQlu5v3

In US, peptic ulcer disease affects 1% of population w/ ~ 54 000admitted to hospital annually w/ bleeding peptic ulcers. But only 10% of PUD pts present w/ upper abdominal pain. Prime causes are Helicobacter pylori infection (42%) & NSAID use (36%) https://t.co/0VvA7lI0MQ https://t.co/YWv4SDNVLC

CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/rBZwUxQ8yw https://t.co/W42YDBnDCa

Don’t Buy Guitars (12.6.2024) This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos;… https://t.co/iaoykvKoCH https://t.co/e0pELS3hMu

ACR24 IL-17 Panel Join Dr. Philip Mease, Dr. Brian Jaros and Dr. Peter Nash as they discuss key takeaways on IL-17 presentations and data presented at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/04bW7vaMTQ https://t.co/0rTglbW75u